|Articles|June 10, 2011

Podcast Interview: Chris Garabedian, CEO, AVI BioPharma

In our latest podcast, Chris Garabedian, CEO at AVI BioPharma, discusses his company's $291 million contract with the Defense Department, and how RNA-based therapeutics are being used to combat infectious diseases.

Interview: Chris Garabedian

Chris Garabedian, CEO at AVI BioPharma, discusses his company's $291 million contract with the Defense Department, and how RNA-based therapeutics are being used to combat infectious diseases.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related Content

Stock.adobe.com

HHS Confirms Four Senior FDA Leaders, Including Agency's First-Ever AI Deputy Commissioner

September 9th 2026

Mark Cziraky

Trusted Research Environments Are Reshaping Real-World Data Access: Q&A with Mark Cziraky

ByMike Hollan,Mark Cziraky

September 7th 2026

stock.adobe.com FDA approval

FDA Approves Zanvastro for Alexander Disease in Pediatrics & Adults

ByNicholas Jacobus

September 4th 2026

Nate Hill, CEO, Strive Pharmacy

What's Next for Compounded Peptides: Q&A with Nate Hill

ByNicholas Jacobus,Nate Hill

September 4th 2026

Mark Cziraky

The Mechanics of Analyzing Linked Data Sets

ByMike Hollan,Mark Cziraky

September 3rd 2026

Trending on PharmExec

The Agentic AI Revolution in Biopharma

How Cortisol-Targeted Approaches Might be Paired with GLP-1 Medications

Artisan Partners’ Director Calls for Novartis Board Shake-Up

Novartis Investors Share Concerns Over M&A Strategy: Report

340B Under Pressure: Inside Pharma's Push for Greater Clarity